Evidence map›Paper›PMID 37350958›Full record

ArticleFrontiers in immunology2023

The Wiskott-Aldrich syndrome protein is required for positive selection during T-cell lineage differentiation.

Melissa Pille, John Avila, Guillem Sanchez Sanchez, Glenn Goetgeluk, Stijn De Munter, Hanne Jansen, Lore Billiet, Karin Weening, Haipeng Xue, Sarah Bonte and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Rediscovering the human thymus through cutting-edge technologies.The Journal of experimental medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Melissa PilleLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
John AvilaBrown Foundation Institute of Molecular Medicine, Mc Govern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.
Guillem Sanchez SanchezDepartment of Pharmacotherapy and Pharmaceutics, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Glenn GoetgelukLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Stijn De MunterLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Hanne JansenLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Lore BillietLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Karin WeeningLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Haipeng XueBrown Foundation Institute of Molecular Medicine, Mc Govern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.
Sarah BonteCancer Research Institute Ghent (CRIG), Ghent, Belgium.
Joline IngelsLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Laurenz De CockLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Eva PascalLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Lucas DeseinsLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Tessa KerreDepartment of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.
Tom TaghonLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Georges LeclercqLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
David VermijlenDepartment of Pharmacotherapy and Pharmaceutics, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Brian DavisBrown Foundation Institute of Molecular Medicine, Mc Govern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.
Bart VandekerckhoveLaboratory of Experimental Immunology, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Ghent University · BEBrown Foundation · USCancer Research Institute Ghent · BEGhent University Hospital · BEUniversité Libre de Bruxelles · BEWalloon Excellence in Lifesciences and Biotechnology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Wiskott-Aldrich syndrome (WAS) is an X-linked primary immune deficiency caused by a mutation in the WAS gene. This leads to altered or absent WAS protein (WASp) expression and function resulting in thrombocytopenia, eczema, recurrent infections, and autoimmunity. In T cells, WASp is required for immune synapse formation. Patients with WAS show reduced numbers of peripheral blood T lymphocytes and an altered T-cell receptor repertoire.

Indexed as

Wiskott-Aldrich SyndromeWiskott-Aldrich Syndrome ProteinAnimalsCell DifferentiationCell LineageHumansMiceReceptors, Antigen, T-CellReceptors, Antigen, T-CellWiskott-Aldrich Syndrome ProteinATOCRISPR/Cas9INDELprimary immunodeficienciesT-cell developmentT-cell repertoireWiskott Aldrich syndrome

Identifiers

PMID37350958
PMCPMC10282776
OpenAlexW4379648637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.